Be the first to know

Never miss an update from iBio. Did you know that during reporting season, the announcements from NYSEMKT:IBIO often move the market?

iBio (NYSEMKT:IBIO) Company Logo

By joining StockLight, you agree to our Terms & Conditions and Privacy Policy
Create Alert Follow IBIO

iBio (IBIO)

US NYSEMKT:IBIO (348M)

1.93
-0.05 (-2.52%)
4:30pm Friday Oct 23 EDT
LOADING
Loading price chart..

Summary

Current Price: $1.93
52w High/Low: $0.05 - 7.45
Market Cap: 348M
Price/Earnings: -1.97
Dividend Yield: -
Volume/Average: 3.1M - 10.8M
iBio (NYSEMKT:IBIO) Company Logo
iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics... More
iBio (NYSEMKT:IBIO) Company Logo

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. The firm operates through the iBio, Inc. and iBio CDMO business segments. The company was founded by Robert B. Kay on April 15, 1993 and is headquartered in Bryan, TX.

Annual Reports

iBio (IBIO) 10-K Annual Report Sep 28th 2020
2020
(90kb)
iBio (IBIO) 10-K Annual Report Aug 26th 2019
2019
(808kb)
iBio (IBIO) 10-K Annual Report Sep 18th 2018
2018
(809kb)
iBio (IBIO) 10-K Annual Report Sep 15th 2017
2017
(710kb)
iBio (IBIO) 10-K Annual Report Oct 13th 2016
2016
(717kb)

Dividend History

No dividends found.

Quantitative Ratios

Stock Ratios Locked
You viewed 3 companies today
Ratios will be unlocked
again tomorrow or;

Unlock these ratios,
configure alerts
and much more...

Download StockLight

All Ratios, Alerts and other features are available in our iOS and Android apps:
Download on iOS Download on Android

We are working on updating this web app to fully enable Quantitative Ratios. All other current web features including annual reports, price sensitive announcements, dividends and earnings transcripts are free to use here on our web app.
Implied Growth
46.3%
 
41.6%
 
 
Industry Avg
IBIO

AVERAGE: iBio exhibits an implied growth ratio which is within a 15% range of the industry average for biotechnology stocks listed on the NYSEMKT. IBIO calculation: 10% - (-$0.61 / $1.93) = 41.6% more
Price / Book
7.5
 
6.1
 
 
Industry Avg
IBIO

ATTRACTIVE: iBio exhibits a price/book ratio which is less than the industry average for biotechnology stocks listed on the NYSEMKT. more
Price / Sales
30.0
 
74.0
 
 
Industry Avg
IBIO

UNATTRACTIVE: iBio exhibits a price/sales ratio which exceeds the industry average for biotechnology stocks listed on the NYSEMKT. more

Company News

3 Popular Robinhood Stocks That Could Realistically Double Within 1 Year
October 8th, 2020 - Motley Fool

Here's what it would take. Keith Speights Popularity isn't necessarily a good thing. There have been plenty of popular stocks in the past that eventually flamed out.But popularity isn't necessarily a bad thing, either. For example, quite a few of ...

Why iBio Stock Is Soaring Today
September 9th, 2020 - Motley Fool

The company is advancing its most-promising vaccine candidate for the novel coronavirus. Prosper Junior Bakiny Shares of iBio (NYSEMKT:IBIO) were up by 6.8% as of 11:38 a.m. EDT after climbing by as much as 19.5% earlier today, following the compa...

Why iBio Stock Jumped Today
August 28th, 2020 - Motley Fool

The biotech struck a licensing deal for a potential coronavirus treatment. Joe Tenebruso Shares of iBio (NYSEMKT:IBIO) climbed on Friday after the biologics manufacturer announced an exclusive global license agreement with Planet Biotechnology for...

These 5 Healthcare Stocks Are the Biggest Winners in 2020
August 27th, 2020 - Motley Fool

It's not a surprise that all five of these stocks are engaged in the fight against the novel coronavirus. Taylor Carmichael Plenty of healthcare stocks are faltering this year. Some companies are struggling to get their products in front of patien...

Why ADMA Biologics, iBio, and Kamada Are Jumping Today
August 24th, 2020 - Motley Fool

The FDA's emergency use authorization of convalescent plasma therapy is sending these three stocks higher today. George Budwell At a news conference Sunday, President Donald Trump announced that the Food and Drug Administration issued an emergency...

Why Novavax, Vaxart, Sorrento Therapeutics, and Other Coronavirus Stocks Plummeted Today
August 12th, 2020 - Motley Fool

Major new developments in the race for a COVID-19 vaccine are driving investors to reevaluate their positions. Joe Tenebruso Coronavirus-related stocks declined sharply on Wednesday, extending their losses following Russia's announcement on Tuesda...

Better Coronavirus Stock: iBio vs. Vaxart
August 7th, 2020 - Motley Fool

These two small-cap biotech stocks have intriguing COVID-19 vaccine candidates. Keith Speights iBio Pharma (NYSEMKT:IBIO) and Vaxart (NASDAQ:VXRT) rank as two of the biggest winners so far this year among small-cap biotechs with coronavirus progra...